News
SDZXF
81.25
NaN%
--
Sandoz boosts European biosimilar capacity with new Slovenian plant
TipRanks · 5d ago
Sandoz wins Canada nod for generic Ozempic; inks licensing deal for generic Hemlibra
Seeking Alpha · 09/18 12:24
mAbxience, Sandoz sign collaboration agreement for biosimilar access
TipRanks · 09/18 10:25
Sandoz joins mAbxience to develop emicizumab biosimilar and expand haemophilia pipeline
TipRanks · 09/18 05:33
Sandoz Wins Canadian Approval for Generic Semaglutide, Targeting Growing GLP-1 Market
TipRanks · 09/18 05:33
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Seeking Alpha · 09/17 18:21
Sandoz price target raised to CHF 72 from CHF 66 at Berenberg
TipRanks · 09/11 13:35
Berenberg Bank Reaffirms Their Hold Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 09/11 08:35
Analysts Offer Insights on NA Companies: Sandoz Group Ltd (OtherSDZXF), Figure Technology Solutions, Inc. Class A (FIGR) and Navan, Inc. Class A (NAVN)
TipRanks · 09/10 12:30
Switzerland's Sandoz aims to double sales by 2035 in expanded biosimilars push
Seeking Alpha · 09/08 09:38
Barclays Reaffirms Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 09/08 07:05
Sandoz Unveils Bio100 Plan to Drive Golden Decade of Biosimilars
TipRanks · 09/08 05:32
Sandoz: More Than A Generic Company, But Too Expensive Here
Seeking Alpha · 09/04 16:59
RBC Capital Remains a Hold on Sandoz Group Ltd (SDZXF)
TipRanks · 09/04 07:25
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Seeking Alpha · 08/31 14:50
Sandoz initiated with a Buy at Erste Group
TipRanks · 08/27 15:50
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
Seeking Alpha · 08/19 13:22
Jefferies Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 08/17 12:29
Sandoz expands biosimilar pipeline with major Henlius collaboration
TipRanks · 08/17 00:32
Sandoz price target raised to CHF 80 from CHF 75 at JPMorgan
TipRanks · 08/10 19:10
More
Webull provides a variety of real-time SDZXF stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZXF
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.